Your browser doesn't support javascript.
loading
Merkel Cell Carcinoma: New Trends.
Zwijnenburg, Ellen M; Lubeek, Satish F K; Werner, Johanna E M; Amir, Avital L; Weijs, Willem L J; Takes, Robert P; Pegge, Sjoert A H; van Herpen, Carla M L; Adema, Gosse J; Kaanders, Johannes H A M.
Afiliação
  • Zwijnenburg EM; Department of Radiation Oncology, Radboudumc, 6525GA Nijmegen, The Netherlands.
  • Lubeek SFK; Department of Dermatology, Radboudumc, 6525GA Nijmegen, The Netherlands.
  • Werner JEM; Department of Surgery, Radboudumc, 6525GA Nijmegen, The Netherlands.
  • Amir AL; Department of Pathology, Radboudumc, 6525GA Nijmegen, The Netherlands.
  • Weijs WLJ; Department of Maxillofacial Surgery, Radboudumc 6525GA Nijmegen, The Netherlands.
  • Takes RP; Department of Head and Neck Surgery, Radboudumc, 6525GA Nijmegen, The Netherlands.
  • Pegge SAH; Department of Radiology and Nuclear Medicine, Radboudumc, 6525GA Nijmegen, The Netherlands.
  • van Herpen CML; Department of Medical Oncology, Radboudumc, 6525GA Nijmegen, The Netherlands.
  • Adema GJ; Department of Radiation Oncology, Radboudumc, 6525GA Nijmegen, The Netherlands.
  • Kaanders JHAM; Department of Radiation Oncology, Radboudumc, 6525GA Nijmegen, The Netherlands.
Cancers (Basel) ; 13(7)2021 Mar 31.
Article em En | MEDLINE | ID: mdl-33807446
ABSTRACT
Merkel cell carcinoma (MCC) is a rare neuroendocrine tumor of the skin mainly seen in the elderly. Its incidence is rising due to ageing of the population, increased sun exposure, and the use of immunosuppressive medication. Additionally, with the availability of specific immunohistochemical markers, MCC is easier to recognize. Typically, these tumors are rapidly progressive and behave aggressively, emphasizing the need for early detection and prompt diagnostic work-up and start of treatment. In this review, the tumor biology and immunology, current diagnostic and treatment modalities, as well as new and combined therapies for MCC, are discussed. MCC is a very immunogenic tumor which offers good prospects for immunotherapy. Given its rarity, the aggressiveness, and the frail patient population it concerns, MCC should be managed in close collaboration with an experienced multidisciplinary team.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Tipo de estudo: Screening_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Tipo de estudo: Screening_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Holanda